These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15808545)

  • 1. Antigen-specific T-lymphocyte responses in acute and chronic syngeneic graft-versus-host disease.
    Hess AD; Thoburn CJ; Miura Y; Bright EC
    Transplant Proc; 2005; 37(1):53-6. PubMed ID: 15808545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease.
    Thoburn CJ; Miura Y; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):591-603. PubMed ID: 15319771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
    Hess AD; Thoburn CJ; Chen W; Bright AE
    Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression.
    Fischer AC; Ruvolo PP; Burt R; Horwitz LR; Bright EC; Hess JM; Beschorner WE; Hess AD
    J Immunol; 1995 Apr; 154(8):3713-25. PubMed ID: 7706714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease.
    Chen W; Thoburn C; Hess AD
    J Immunol; 1998 Dec; 161(12):7040-6. PubMed ID: 9862741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complexity of effector mechanisms in cyclosporine-induced syngeneic graft-versus-host disease.
    Hess AD; Thoburn CJ; Chen W; Horwitz LR
    Biol Blood Marrow Transplant; 2000; 6(1):13-24. PubMed ID: 10707995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease.
    Hess AD; Fischer AC; Horwitz L; Bright EC; Laulis MK
    J Immunol; 1994 Jul; 153(1):400-11. PubMed ID: 8207251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease. Role of CD4+ and CD8+ T lymphocyte subsets.
    Hess AD; Fischer AC; Beschorner WE
    J Immunol; 1990 Jul; 145(2):526-33. PubMed ID: 1973185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune-mediated vasculopathy.
    Chen W; Thoburn CJ; Miura Y; Sommer M; Hruban R; Qian Z; Baldwin W; Hess AD
    Clin Immunol; 2001 Jul; 100(1):57-70. PubMed ID: 11414746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th1 cytokines and NK cells participate in the development of murine syngeneic graft-versus-host disease.
    Flanagan DL; Jennings CD; Bryson JS
    J Immunol; 1999 Aug; 163(3):1170-7. PubMed ID: 10415011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells.
    Hess AD; Thoburn CJ
    Biol Blood Marrow Transplant; 2006 May; 12(5):518-29. PubMed ID: 16635787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host resistance to cyclosporine induced syngeneic graft-versus-host disease. Requirement for two distinct lymphocyte subsets.
    Fischer AC; Laulis MK; Horwitz L; Beschorner WE; Hess A
    J Immunol; 1989 Aug; 143(3):827-32. PubMed ID: 2526175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.
    Brandon JA; Jennings CD; Kaplan AM; Bryson JS
    J Immunol; 2011 Mar; 186(6):3726-34. PubMed ID: 21296982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous graft-vs-host disease: mechanisms and potential therapeutic effect.
    Hess AD; Jones RC; Santos GW
    Bone Marrow Transplant; 1993; 12 Suppl 3():S65-9. PubMed ID: 8124261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen.
    Hess AD; Thoburn CJ; Miura Y; Bright EC
    Clin Immunol; 2005 Mar; 114(3):307-19. PubMed ID: 15721842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of V beta T-cell receptor repertoire of effector mechanisms in acute and chronic graft versus host disease.
    Fischer AC; Ruvolo PP; Horwitz LR; Hess AD
    Transplant Proc; 1995 Feb; 27(1):1366-9. PubMed ID: 7878914
    [No Abstract]   [Full Text] [Related]  

  • 17. Graft-versus-host disease after autologous bone marrow transplantation: a realistic expectation?
    Niederwieser D; Eibl B; Nachbaur D
    Wien Med Wochenschr; 1995; 145(2-3):25-7. PubMed ID: 7762248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promiscuous recognition of major histocompatibility complex class II determinants in cyclosporine-induced syngeneic graft-versus-host disease: specificity of cytolytic effector T cells.
    Hess AD; Thoburn C; Horwitz L
    Transplantation; 1998 Mar; 65(6):785-92. PubMed ID: 9539089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nephritogenic T cell response in murine chronic graft-versus-host disease.
    Meyers CM; Tomaszewski JE; Glass JD; Chen CW
    J Immunol; 1998 Nov; 161(10):5321-30. PubMed ID: 9820505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.